Pfizer, the manufacturer of one of the most widely distributed ‘vaccines’ being used to halt the Covid-19 pandemic, has openly admitted that the clinical trials involving young people were carried out in such a considerably reduced period of time that it has proved impossible to determine the degree of risk that myocarditis poses to children as an adverse reaction.
In a shocking report presented to the FDA on October 26th 2021 titled ‘Vaccine and Related Biological Products Advisory Committee’, Pfizer recognise that the clinical trials were too short to establish if the experimental gene therapy put young people at risk of myocarditis, an inflammation of the heart muscle which can prove fatal. This particular infliction has seen an exponential increase in recent times in young, healthy people since the rollout of MRNA injection under Emergency Use Authorisation (EUA), and has been particularly prominent in sports players; according to FIFA’s own figures, 108 registered football players and coaches have died in the past six months, an increase of over 500% for 2021.
According to page 11 of the document, Pfizer not only recognises that the clinical trials were rushed but that the number of participants was also far too reduced to detect the potential risk of myocarditis in children aged from 5 to 12 years old. The document goes on to confirm that long term safety data is required to evaluate the risk of myocarditis/pericarditis and will be submitted in a follow-up study, to be published in 5 years. Despite this damning report, the FDA subsequently issued a EUA thus making the K0 B1T injection readily available for children as young as 5. The presence of Tromethamine in the vaccine, a drug that is often employed to treat cardiac arrests and bypass patients, may hold the key to why myocarditis is making a sudden appearance in once healthy young people.
The EUA was issued based on safety data that Pfizer and BioNTech published on July 28th, 2021, and should raise some serious concerns since fundamental data emerging from the clinical trials was misrepresented. The safety report claims that out of 22,000 participants, 15 people died after having received the injection as opposed to 14 who had received the placebo. Most of the deaths were of course linked to ‘underlying health conditions, namely cardiac-related issues. However, in this latest report, figures for the same period have now increased to 21 in the receptor group and 17 in the placebo group but still find no correlation between the deaths and the injection.
It is also important to highlight that the original safety report, published in July, was already four months old and therefore any deaths linked to the trials after the 13th of March 2021 were not accounted for; the death count appears as an afterthought in the appendix of the paper despite being one of the most important features in any drug safety study.
The true figures will likely never be established since Pfizer and BioNTech admit that once the FDA gave its approval for the drug to be administered under the Emergency Use Authorisation, the majority of the receptors of the placebo have since been fully vaccinated. However, what we can deduce from their recent revelations is that any child that has partaken in the gene therapy program and been injected with the K0 B1T injection manufactured by Pfizer, is indeed part of a short, badly organised and potentially life-changing or even deadly experiment.